At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
BMS-986177 Oral Solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and Oral Solution in Healthy Participants With Additional Food Effect Comparison of a Spray-Dried Dispersion Formulation of Milvexian in Capsules
In Brief
A Phase 1 clinical trial evaluating BMS-986177 Oral Solution, [14C]BMS-986177 Solution for Infusion, and 1 other intervention for Healthy Volunteers. Completed, enrolled 17 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the absolute oral bioavailability (amount of drug entering the bloodstream) of spray-dried dispersion (SDD) milvexian capsules in the fed and fasted states, and to bridge the exposures seen using only the oral solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartJul 2021
Primary CompletionAug 2021
Study CompletionOct 2021
TodayJul 2026
First PostedJul 16, 2021
Enrollment StartJul 16, 2021
Primary CompletionAug 22, 2021
Study CompletionOct 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 5.0 years ago
Interventions
BMS-986177 Oral Solutiondrug
Specified dose on specified days
[14C]BMS-986177 Solution for Infusiondrug
Specified dose on specified days
BMS-986177 Spray-dried Dispersion Capsulesdrug
Specified dose on specified days